S. Gill

S. Gill, A. Sha, S. Abadi, 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis.

D. Sargent, S. Gill, Q. Shi, 2015, Clinical colorectal cancer.

Translating IDEA to Practice and Beyond: Managing Stage II and III Colon Cancer.

J. Meyerhardt, S. Gill, Christine M. Veenstra, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer

R. Goldberg, S. Gill, 2004, Cancer Chemotherapy and Pharmacology.

Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.

Aalok Kumar, H. Kennecke, S. Gill, 2015, Clinical colorectal cancer.

Update on the Colon Health and Life-Long Exercise Change Trial: A Phase III Study of the Impact of an Exercise Program on Disease-Free Survival in Colon Cancer Survivors

C. Friedenreich, K. Courneya, D. Tu, 2014, Current Colorectal Cancer Reports.

Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators.

D. Sargent, A. Bardia, C. Loprinzi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Duration of adjuvant therapy for colorectal cancer: are we overtreating our patients?

R. Goldberg, S. Gill, 2005, Nature Clinical Practice Oncology.

Treatment patterns and survival outcomes of early-onset colorectal cancer patients in Alberta, Canada: a population-based study.

S. Gill, D. Boyne, W. Cheung, 2022, Cancer treatment and research communications.

Impact of irinotecan and oxaliplatin on overall survival in patients with metastatic colorectal cancer: a population-based study.

H. Kennecke, S. Gill, B. Melosky, 2007, Journal of oncology practice.

Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.

S. Gill, Cheryl Ho, S. O'Reilly, 2005, Clinical colorectal cancer.

New developments in therapy for colorectal cancer

R. Goldberg, S. Gill, 2003, Current Oncology Reports.

Consensus recommendations for the use of anti-egfr therapies in metastatic colorectal cancer.

H. Kennecke, S. Gill, S. Dowden, 2010, Current oncology.

Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.

H. Kennecke, S. Gill, R. Woods, 2016, Clinical colorectal cancer.

Evolving end points for clinical trials in advanced colorectal cancer

D. Sargent, S. Gill, 2009 .

Colorectal cancer.

R. Goldberg, S. Gill, A. W. Blackstock, 2007, Mayo Clinic proceedings.

Assessing how health information needs of individuals with colorectal cancer are met across the care continuum: an international cross-sectional survey

S. Gill, A. Safari, M. D. de Vera, 2020, BMC cancer.

Cautious optimism-the current role of immunotherapy in gastrointestinal cancers.

S. Gill, S. Mendis, 2019, Current oncology.

A phase II trial of the effect of perindopril on hand–foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC

S. Gill, C. Kollmannsberger, B. Melosky, 2018, Cancer Chemotherapy and Pharmacology.

Factors associated with delayed time to adjuvant chemotherapy in stage iii colon cancer.

H. Kennecke, S. Gill, R. Woods, 2014, Current oncology.

Type B lactic acidosis from fluorouracil in fluorouracil, oxaliplatin and leucovorin treatment for carcinoma of the colon in a hemodialysis patient

S. Gill, M. Copland, E. Yeung, 2018, Clinical kidney journal.

The identification of Lynch syndrome in British Columbia.

D. Huntsman, S. Gill, L. Armstrong, 2009, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Real-world treatment attrition rates in advanced esophagogastric cancer

S. Gill, J. Loree, D. Renouf, 2020, World journal of gastroenterology.

Integration of Whole-Genome Sequencing With Circulating Tumor DNA Analysis Captures Clonal Evolution and Tumor Heterogeneity in Non-V600 BRAF Mutant Colorectal Cancer.

Steven J. M. Jones, Ryan D. Morin, M. Marra, 2020, Clinical colorectal cancer.

Comparison of Treatment, Cost, and Survival in Patients With Metastatic Colorectal Cancer in Western Washington, United States, and British Columbia, Canada.

S. Ramsey, H. Kennecke, S. Gill, 2020, JCO oncology practice.

Trends in the Incidence of Young-Onset Colorectal Cancer With a Focus on Years Approaching Screening Age: A Population-Based Longitudinal Study

M. Raval, S. Gill, E. C. Sayre, 2021, Journal of the National Cancer Institute.

Effect of M1a andM1b Category in Metastatic Colorectal Cancer

Blanke, H. Kennecke, S. Gill, 2014 .

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

S. Cha, R. Labianca, D. Sargent, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early-Age-Onset Colorectal Cancer in Canada: Evidence, Issues and Calls to Action

Clarence K. Wong, D. Brenner, S. Gill, 2022, Current oncology.

The Impact of Geography in Hepatocellular Carcinoma: A Retrospective Population Based Study

S. Gill, J. Davies, V. Zaborska, 2021, Current oncology.

Racial differences in the incidence of colorectal cancer.

S. Gill, B. Salh, E. Yoshida, 2010, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147.

D. Sargent, E. Basch, J. Sloan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance).

D. Sargent, R. Goldberg, A. Shields, 2017 .

Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

D. Sargent, J. Galon, A. Shields, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Characterizing the KRAS G12C mutation in metastatic colorectal cancer: a population-based cohort and assessment of expression differences in The Cancer Genome Atlas

S. Yip, Lucas Swanson, S. Gill, 2022, Therapeutic advances in medical oncology.

Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer

R. Goldberg, T. Smyrk, N. Foster, 2021, JNCI cancer spectrum.

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.

P. Schaefer, N. Foster, J. Kugler, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline

S. Gill, J. Loree, B. Sheffield, 2022, Therapeutic advances in medical oncology.

Assessing how health information needs of individuals with colorectal cancer are met across the care continuum: an international cross-sectional survey

S. Gill, A. Safari, M. D. de Vera, 2020, BMC Cancer.

Abstract 5261: Irinophore C, a liposomal formulation of irinotecan, has anti-vascular effects in primary tumors of colorectal cancer grown orthotopically in mice

D. Owen, S. Gill, I. Tai, 2012 .

Eastern Canadian colorectal cancer consensus conference: application of new modalities of staging and treatment of gastrointestinal cancers.

C. Giacomantonio, D. Hedley, K. Jhaveri, 2012, Current oncology.

Raising the Bar in Advanced Pancreatic Cancer

S. Gill, 2017 .

Reply to M. Uccello et al.

S. Gill, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial.

A. Benson, J. Galon, R. Goldberg, 2022, JCO precision oncology.

Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

D. Sargent, A. Benson, J. Galon, 2018 .

Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).

D. Sargent, A. Benson, J. Galon, 2017 .

Isolated Loss of PMS2 Expression in Colorectal Cancers: Frequency, Patient Age, and Familial Aggregation

D. Sargent, J. Hopper, S. Thibodeau, 2005, Clinical Cancer Research.

Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147.

D. Sargent, S. Thibodeau, R. Goldberg, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147

D. Sargent, S. Thibodeau, R. Goldberg, 2010 .

PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT).

M. Moore, S. Gill, Y. Ko, 2014 .

Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.

A. Carrato, F. Ciardiello, S. Gill, 2016, Cancer treatment reviews.

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

D. Tu, S. Gill, S. Welch, 2022, Nature Communications.

171 Sorafenib for Advanced Hepatocellular Carcinoma

S. Gill, E. Yoshida, M. Suen, 2012 .

The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: a multicentered retrospective analysis

S. Gill, S. Welch, W. Cheung, 2020, BMC Cancer.

Report from the Ready for the Next Round Thought-Leadership Roundtables on Building Resilience in Cancer Care and Control in Canada-Colorectal Cancer Canada; 2021

Eva G. Villalba, S. Gill, W. Cheung, 2022, Current oncology.

A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer

M. Moore, W. Vervenne, C. Verslype, 2008 .

Capecitabine-induced cerebellar toxicity.

S. Gill, D. Renouf, 2006, Clinical colorectal cancer.

A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis.

S. Gill, P. Chen, B. Carr, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response to 5-fluorouracil in metastatic extramammary Paget disease of the scrotum presenting as pancytopenia and back pain

S. Gill, M. Levesque, K. M. Beleznay, 2009, Current oncology.

Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?

F. Sinicrope, S. Gill, 2005, Seminars in oncology.

First-Line Treatment Strategies to Improve Survival in Patients with Advanced Colorectal Cancer

R. Goldberg, S. Gill, 2004, Drugs.

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults †

H. Feilotter, S. Banerji, M. Tsao, 2021, Current oncology.

Adjuvant Therapy with Raltitrexed in Patients with Colorectal Cancer Intolerant of 5-Fluorouracil: British Columbia Cancer Agency Experience

S. Gill, B. Pharm., K. Wilson, 2007, Cancer investigation.

Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)

D. Sargent, R. Goldberg, A. Shields, 2016, The oncologist.

Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center.

E. Cook, N. Le, A. Shah, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PRACTICE GUIDELINE SERIES

M. Sherman, S. Gill, P. Metrakos, 2015 .

Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer

Ryan D. Morin, Trevor J Pugh, O. Griffith, 2012, The Pharmacogenomics Journal.

Review article: colorectal cancer chemotherapy.

R. Goldberg, S. Gill, R. Thomas, 2003, Alimentary pharmacology & therapeutics.

Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.

D. Sargent, S. Thibodeau, R. Goldberg, 2014, Clinical colorectal cancer.

Intraperitoneal Treatment for Peritoneal Mucinous Carcinomatosis of Appendiceal Origin After Operative Management: Long-term Follow-up of the Mayo Clinic Experience

J. Donohue, S. Gill, RobertI Miller, 2009, Annals of surgery.

Report from the 17th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Edmonton, Alberta; 11-12 September 2015.

S. Gill, S. Dowden, H. Lim, 2016, Current oncology.

Use of random skin biopsy to diagnose intravascular lymphoma presenting as fever of unknown origin.

S. Gill, B. Melosky, L. Haley, 2003, The American journal of medicine.

Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer.

A. Pollett, S. Gill, S. Kamel‐Reid, 2011, Current oncology.

Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis

S. Gill, G. Wells, D. Jonker, 2014, BMC Cancer.

Adjuvant chemotherapy use and outcomes of patients with high‐risk versus low‐risk stage II colon cancer

Aalok Kumar, H. Kennecke, S. Gill, 2015, Cancer.

LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

D. Tu, S. Gill, S. Welch, 2020 .

Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes.

S. Gill, S. Dowden, B. Colwell, 2014, Cancer treatment reviews.

Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX

S. Gill, W. Cheung, D. Renouf, 2017, American journal of clinical oncology.

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.

W. Scheithauer, E. Van Cutsem, M. Moore, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Massive bleeding on a bladder protectant: a case report of pentosan polysulfate sodium-induced coagulopathy.

S. Gill, L. Vickars, Abeed Jamal, 2002, Archives of internal medicine.

Health information seeking behaviors among individuals with young-onset and average-onset colorectal cancer: an international cross-sectional survey

S. Gill, M. D. de Vera, J. Loree, 2020, Supportive Care in Cancer.

Eastern Canadian Colorectal Cancer Consensus Conference: standards of care for the treatment of patients with rectal, pancreatic, and gastrointestinal stromal tumours and pancreatic neuroendocrine tumours.

S. Gill, S. Welch, J. Biagi, 2013, Current oncology.

Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer

S. Gill, W. Cheung, S. Kong, 2019, American journal of clinical oncology.

Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer

H. Wong, H. Kennecke, S. Gill, 2018, American journal of clinical oncology.

Author ' s response to reviews Title : Chemotherapy for advanced pancreatic cancer : A systematic review and network meta-analysis

S. Gill, G. Wells, D. Jonker, 2014 .

Beyond the Knife: The Evolving Nonsurgical Management of Oligometastatic Colorectal Cancer.

S. Gill, Ricky A. Sharma, David M. Liu, 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?

D. Sargent, S. Gill, 2006, The oncologist.

Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.

D. Tu, J. Zalcberg, J. Simes, 2018, The lancet. Gastroenterology & hepatology.

Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical Oncologists

S. Gill, Selina K. Wong, L. Gondara, 2021, Current oncology.

Comparison of chemotherapy use, cost, and survival in patients with metastatic colorectal cancer in Western Washington and British Columbia.

H. Kennecke, S. Gill, C. Speers, 2018, Journal of Clinical Oncology.

Eligibility for Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

S. Gill, J. Loree, D. Renouf, 2020, American journal of clinical oncology.

Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer

D. Horsman, S. Gill, S. Young, 2009, International journal of cancer.

Canadian Colorectal Cancer Screening Guidelines: Do They Need an Update Given Changing Incidence and Global Practice Patterns?

S. Peacock, S. Gill, F. Donnellan, 2021, Current oncology.

Population-based screening for BRAF V600E in metastatic colorectal cancer (mCRC) to reveal true prognosis.

A. Karsan, Lucas Swanson, S. Kopetz, 2019, Journal of Clinical Oncology.

Paraneoplastic Sensory Neuronopathy and Spontaneous Regression of Small Cell Lung Cancer

S. Gill, J. Dalmau, N. Murray, 2003, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Presentation and outcomes of patients aged 30 years and younger with colorectal cancer: a 20-year retrospective review

S. Gill, J. Al-barrak, 2011, Medical oncology.

Trends in the epidemiology of young-onset colorectal cancer: a worldwide systematic review

S. Gill, E. C. Sayre, M. D. de Vera, 2020, BMC Cancer.

Adjuvant therapy for node-negative colon cancer

R. Goldberg, S. Gill, 2002 .

A Hypothesis-Generating Study Using Electrophysiology to Examine Cognitive Function in Colon Cancer Patients.

S. Hayden, S. Gill, K. Campbell, 2019, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

Well-Differentiated Grade 3 Neuroendocrine Tumors

S. Gill, D. Farnell, J. Loree, 2022, Pancreas.

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High‐Risk Stage III (pT4 and/or N2) Colon Cancer—A UNICANCER GI‐PRODIGE Trial

S. Gill, J. Emile, J. Taïeb, 2019, Clinical colorectal cancer.

A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer

L. Seymour, D. Hedley, M. Moore, 2012, Investigational New Drugs.

Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.

J. Meyerhardt, J. Berlin, A. Morris, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies

S. Gill, 2014, Indian Journal of Medical and Paediatric Oncology.

Reproductive Health Outcomes among Adolescent and Young Adult Cancer Patients: A Systematic Review and Meta-Analysis

S. Gill, M. D. de Vera, G. Hanley, 2023, Cancers.

Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer

A. Benson, J. Galon, R. Goldberg, 2020, JNCI cancer spectrum.

Asian E thnicity-Relate d D ifferences i n G astric C ancer Presentation a nd O utcome A mong P atients T reated a t a Canadian C ancer C enter

E. Cook, N. Le, S. Gill, 2003 .

Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update

J. Meyerhardt, J. Berlin, A. Morris, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 2014.

Duc Hung Le, H. Kennecke, S. Gill, 2015, Current oncology.

Population-based analysis of patients with advanced colorectal cancer: The impact of age on treatment and outcomes

S. Gill, Cheryl Ho, S. O'Reilly, 2005 .

Population-based Screening for BRAFV600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis

A. Karsan, Lucas Swanson, S. Kopetz, 2020, Clinical Cancer Research.

Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis

D. Sargent, B. Bot, Tsung-Teh Wu, 2011, Annals of Surgical Oncology.

Prognostic web‐based models for stage II and III colon cancer

D. Sargent, A. Bardia, C. Loprinzi, 2011, Cancer.

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).

D. Sargent, R. Diasio, Adam M. Lee, 2016, Pharmacogenetics and genomics.

Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147

D. Sargent, P. Newcomb, R. Goldberg, 2016, International Journal of Cancer.

Neutropenia and Relative Dose Intensity on Adjuvant FOLFOX Chemotherapy Are Not Associated with Survival for Resected Colon Cancer

S. Gill, M. Smoragiewicz, K. R. Javaheri, 2014, Journal of Gastrointestinal Cancer.

Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma.

S. Gill, W. Cheung, D. Renouf, 2014, Journal of gastrointestinal oncology.

Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!).

D. Sargent, A. Bardia, C. Loprinzi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Controversies and management of deficient mismatch repair gastrointestinal cancers in the neoadjuvant setting

S. Gill, M. Boutin, 2023, Therapeutic advances in medical oncology.

Trends in the epidemiology of young-onset colorectal cancer: a worldwide systematic review

S. Gill, E. C. Sayre, M. D. de Vera, 2020, BMC Cancer.

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.

R. Labianca, J. Meyerhardt, M. Shah, 2020, European journal of cancer.

Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147.

D. Sargent, J. Sloan, R. Goldberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New targeted therapies in gastrointestinal cancers

R. Goldberg, S. Gill, Rebecca R. Thomas, 2003, Current treatment options in oncology.

New developments in therapy for metastatic colorectal cancer

S. Gill, 2005 .

Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators.

D. Sargent, A. Bardia, C. Loprinzi, 2010, Seminars in oncology.

Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE Trial

C. Friedenreich, K. Courneya, D. Tu, 2016, Cancer Epidemiology, Biomarkers & Prevention.

Trends in chemotherapy utilization for colorectal cancer.

H. Kennecke, S. Gill, D. Renouf, 2008, Clinical colorectal cancer.

Patients’ Perspectives on Health Information Seeking Throughout the Colorectal Cancer Experience: A Qualitative Study

S. Gill, J. Loree, Hallie Dau, 2020 .

Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

D. Tu, S. Gill, S. Welch, 2021 .

The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group

C. Friedenreich, K. Courneya, M. Brundage, 2008, Current oncology.

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

J. Berlin, K. Haustermans, P. Laurent-Puig, 2023, ESMO open.

Patterns of diagnosis for colorectal cancer (CRC): Screening detected versus symptomatic presentation.

S. Gill, S. Smiljanic, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of M1a and M1b category in metastatic colorectal cancer.

H. Kennecke, C. Blanke, S. Gill, 2014, The oncologist.

Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer

S. Gill, M. D. de Vera, J. Loree, 2023, Cancer research communications.

Individual data pooled analyses to improve understanding of adjuvant therapy in colon cancer: Review of the ACCENT collaborative group

D. Sargent, S. Gill, 2008 .

Body Mass Index and Body Surface Area and Their Associations with Outcomes in Stage II and III Colon Cancer

H. Kennecke, S. Gill, R. Woods, 2013, Journal of Gastrointestinal Cancer.

Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma.

M. Sherman, S. Gill, P. Metrakos, 2011, Current oncology.

Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study

D. Sargent, D. Huntsman, Tsung-Teh Wu, 2014, Clinical Cancer Research.

Impact of Tumor Location on Patient Outcomes in Small Bowel Cancers.

S. Gill, J. Loree, D. Renouf, 2021, Clinical colorectal cancer.

Linifanib phase II trial in patients with advanced hepatocellular carcinoma (HCC).

S. Gill, B. Carr, J. Knox, 2010 .

Association of Reducing the Recommended Colorectal Cancer Screening Age With Cancer Incidence, Mortality, and Costs in Canada Using OncoSim

S. Gill, F. Donnellan, M. D. de Vera, 2023, JAMA oncology.

A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)

E. Eisenhauer, L. Seymour, S. Gill, 2008, Investigational New Drugs.

Impact of the COVID-19 Pandemic on the Wellbeing of International Oncology and Hematology Fellows at the Princess Margaret Cancer Center (PMCC)

S. Gill, S. Sridhar, M. Elliot, 2022, Seminars in Oncology.

Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases

H. Kennecke, S. Gill, J. Loree, 2020, Canadian journal of gastroenterology & hepatology.

Efficacy and prognostic factors for y-90 radioembolization (Y-90) in metastatic neuroendocrine tumors with liver metastases.

H. Kennecke, S. Gill, J. Loree, 2018 .

Real-world Impact of Availability of Adjuvant Therapy on Outcomes in Patients With Resected Pancreatic Adenocarcinoma: A Canadian Cancer Agency Experience

S. Gill, D. Owen, Christina A. Kim, 2012, American journal of clinical oncology.

Targeted therapies: Cetuximab, chemotherapy and KRAS status in mCRC

R. Goldberg, S. Gill, 2009, Nature Reviews Clinical Oncology.

A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)

G. Pond, S. Gill, J. Knox, 2008, Investigational New Drugs.

6517 International phase 2 trial of ABT-869 in patients with advanced hepatocellular carcinoma (HCC)

S. Gill, J. Knox, W. Yong, 2009 .

Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.

H. Kennecke, C. Blanke, S. Gill, 2011, Clinical colorectal cancer.

Patterns of Diagnosis for Colorectal Cancer: Screening Detected vs. Symptomatic Presentation

S. Gill, S. Smiljanic, 2008, Diseases of the colon and rectum.

Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study

H. Kennecke, S. Gill, W. Cheung, 2017, American journal of clinical oncology.

Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance)

D. Sargent, P. Newcomb, R. Goldberg, 2018, Cancer Epidemiology, Biomarkers & Prevention.

Report from the 24th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Colorectal Cancer, Richmond, British Columbia, 28–29, October 2022

S. Gill, Jennifer Nuk, T. Phang, 2023, Current oncology.

The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC).

D. Tu, J. Zalcberg, J. Simes, 2014 .

Consensus recommendations for the use of anti- egfr therapies

H. Kennecke, S. Gill, S. Dowden, 2010 .

Phase 2 trial of linifanib (ABT‐869) in patients with unresectable or metastatic hepatocellular carcinoma

S. Gill, P. Ansell, B. Carr, 2013, Cancer.

Cetuximab, chemotherapy and KRAS status in mCRC.

R. Goldberg, S. Gill, 2009, Nature reviews. Clinical oncology.

TREATMENT OF METASTATIC COLORECTAL CANCER Review of recent advances

R. Goldberg, S. Gill, J. Davies, 2005 .

Are we finally moving toward personalized therapy in colorectal cancer?

S. Gill, 2019, Current oncology.

Comparative effectiveness of FOLFIRINOX or nab-paclitaxel plus gemcitabine in locally advanced or metastatic pancreatic cancer: A population-based analysis.

S. Gill, W. Cheung, D. Renouf, 2016 .

Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147

D. Sargent, P. Newcomb, R. Goldberg, 2016, International journal of cancer.

Patterns of presentation, referral, and treatment of hepatocellular carcinoma in a pre-sorafenib era: experience of a Canadian provincial cancer agency.

S. Gill, T. Sundaralingam, 2011, Current oncology.